Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01430351 · ClinicalTrials.gov registry record · Phase 1
Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 144
- Enrollment target
NCT01430351: Clinical Trial Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT01430351 is a Phase 1 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 144 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01430351, a Phase 1 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 144 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of combination chemotherapy in treating patients with glioblastoma multiforme after radiation therapy. Drugs used in chemotherapy, such as temozolomide, memantine hydrochloride, and metformin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing them or stopping them from dividing. Mefloquine may help temozolomide, memantine hydrochloride, and metformin hydrochloride kill more cancer cells by making tumor cells more sensitive to the drug. Giving more than one drug (combination chemotherapy) may kill more tumor cells.
Interventions
- DRUG Temozolomide
- DRUG Metformin Hydrochloride
- DRUG Memantine Hydrochloride
- DRUG Mefloquine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2011-09-14 |
| Est. Completion | 2025-02-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01430351
The ClinicalTrials.gov registry entry for NCT01430351 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 144 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Temozolomide is the first listed.
NCT01430351 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01430351 about?
NCT01430351 is a clinical study titled "Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy". This phase I trial studies the side effects and best dose of combination chemotherapy in treating patients with glioblastoma multiforme after radiation therapy. Drugs used in chemotherapy, such as temozolomide, memantine hydrochloride, and metformin hydrochloride, work in different ways to stop the ...
What is the current status of trial NCT01430351?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 144 participants. The study started on 2011-09-14. Estimated completion is 2025-02-02.
What interventions are being tested in trial NCT01430351?
The interventions under investigation include: Temozolomide (DRUG), Metformin Hydrochloride (DRUG), Memantine Hydrochloride (DRUG), Mefloquine (DRUG).
Who is sponsoring clinical trial NCT01430351?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.